explos
knowledg
technolog
revolution
medicin
patient
care
novel
test
must
brought
clinic
safeti
accuraci
also
time
costeffect
manner
patient
benefit
laboratori
offer
test
consist
current
guidelin
oversight
provid
clinic
laboratori
improv
amend
laboratori
abl
develop
optim
laboratori
procedur
use
inhous
qualiti
improv
program
interlaboratori
comparison
abil
laboratori
adjust
assay
need
improv
result
util
new
sampl
type
incorpor
new
mutat
inform
technolog
posit
aspect
clinic
laboratori
improv
amend
oversight
laboratorydevelop
procedur
laboratori
long
histori
success
servic
patient
oper
clinic
laboratori
improv
amend
seri
detail
clinic
exampl
illustr
qualiti
posit
impact
laboratorydevelop
procedur
patient
care
provid
exampl
also
demonstr
clinic
laboratori
improv
amend
oversight
ensur
accur
reliabl
reproduc
test
clinic
laboratori
field
patholog
offer
opportun
better
understand
scienc
behind
mechan
diseas
lead
innov
new
diagnost
technolog
provid
qualiti
oversight
develop
enorm
impact
live
patient
everi
day
patient
benefit
laboratori
medicin
test
throughout
live
everi
medic
decis
impact
result
laboratori
test
laboratori
result
constitut
major
data
patient
electron
medic
record
procedur
dictat
major
downstream
medic
decis
patient
clinic
laboratori
medic
profession
uniqu
respons
patient
assess
perform
technolog
provid
accur
inform
ensur
appropri
effici
cours
care
understat
say
medic
field
rapidli
chang
technolog
new
genom
data
develop
result
human
genom
project
lead
explos
knowledg
applic
individu
patient
care
promis
precis
medicin
must
continu
innov
integr
novel
diagnost
tool
genom
inform
new
treatment
clinic
practic
consider
technolog
advanc
allow
clinic
laboratori
profession
offer
new
test
provid
inform
ever
often
within
time
frame
allow
rapid
patient
care
better
outcom
nextgener
sequenc
ng
genet
oncolog
malditof
clinic
microbiolog
laboratori
varieti
mass
spectroscopybas
method
clinic
chemistri
allow
precis
rapid
test
demonstr
improv
patient
care
often
thought
laboratori
test
done
reach
diagnosi
done
kit
machin
fact
procedur
done
direct
involv
laboratori
profession
physician
laboratori
test
gener
fulli
encompass
test
kit
often
start
pathologist
examin
tissu
section
bone
marrow
aspir
gram
stain
determin
addit
inform
need
provid
clinician
best
scenario
patient
treat
effect
often
clinic
laboratori
profession
lead
develop
optim
approach
improv
care
fill
clinic
need
involv
process
help
ensur
highest
qualiti
standard
maintain
ongo
develop
novel
method
critic
medicin
must
done
highest
level
safeti
accuraci
yet
simultan
address
grow
demand
lower
cost
medic
care
unit
state
regulatori
oversight
laboratorydevelop
test
procedur
ldp
critic
impact
patient
access
test
diagnosi
current
nation
discuss
regard
optim
regulatori
oversight
laboratori
test
procedur
balanc
need
accuraci
safeti
ensur
new
test
made
avail
patient
safe
expediti
oversight
provid
clinic
laboratori
improv
amend
clia
food
drug
administr
fda
current
exist
clinic
laboratori
must
note
spectrum
test
activ
take
place
clinic
laboratori
activ
rang
complex
procedur
evalu
tissu
biopsi
classif
tumor
cultur
microb
autom
standard
test
fdaapprov
kit
util
activ
take
place
direct
laboratori
profession
accord
detail
requir
clia
fda
review
process
well
suit
diagnost
assay
commerci
market
kit
design
oper
across
spectrum
laboratori
set
laboratori
rang
expertis
current
fda
approv
clearanc
requir
prospect
clinic
trial
data
lengthi
review
process
thu
fda
approv
take
consider
effort
time
invest
need
process
impact
type
test
also
sampl
type
submit
approv
manufactur
must
recov
invest
afterward
addit
fda
approv
vitro
diagnost
ivd
specifi
sampl
type
clinic
purpos
aspect
perform
assay
new
clinic
need
ivd
aris
need
use
new
sampl
type
aris
need
modif
aris
respons
ongo
sometim
rapid
advanc
seen
medicin
incorpor
improv
render
test
ldp
valid
need
ldp
clia
laboratori
caught
regul
need
best
serv
patient
clia
provid
oversight
clinic
laboratori
defin
aspect
laboratori
oper
includ
qualiti
program
requir
clinic
test
personnel
requir
valid
requir
ldp
clia
certif
laboratori
accomplish
sever
deem
agenc
colleg
american
pathologist
cap
new
york
state
depart
health
nysdoh
organ
provid
oper
guidelin
perform
onsit
inspect
base
upon
checklist
develop
via
consensu
laboratori
expert
includ
hundr
page
requir
data
point
complianc
clia
built
clinic
laboratori
oper
mechan
data
collect
train
profici
test
pt
test
implement
laboratori
subject
unannounc
inspect
must
demonstr
satisfactori
perform
characterist
test
offer
ensur
result
accur
test
review
fda
ldp
laboratori
must
go
rigor
valid
process
offer
test
clinic
use
clia
valid
data
collect
laboratori
subject
ongo
peer
review
particular
organ
deem
statu
overse
laboratori
cap
nysdoh
conduct
rigor
peerinspect
use
detail
criteria
develop
specif
molecular
patholog
laboratori
also
particip
requir
pt
demonstr
assay
qualiti
interlaboratori
data
share
assess
often
led
cap
lead
ongo
broad
improv
ldp
recent
public
document
present
exampl
specif
ldp
clinic
valid
test
interpret
use
clinician
reproduc
laboratori
data
question
rais
concern
safeti
efficaci
categori
test
enhanc
regulatori
oversight
propos
help
ensur
laboratori
deliv
meaning
highqual
result
patient
howev
addit
regul
potenti
slow
innov
limit
delay
patient
access
novel
test
impact
clinic
care
well
add
redund
report
effort
signific
cost
expand
oversight
laboratori
revis
clia
process
also
propos
http
wwwcaporgshowproperti
nodepathucmconcon
tribut
tiveproposalpdf
access
april
effort
illustr
need
posit
impact
laboratorydevelop
procedur
patient
care
follow
seri
vignett
assembl
case
time
highqual
laboratorydevelop
procedur
fill
key
clinic
need
impact
patient
care
summar
possibl
data
describ
interlaboratori
comparison
provid
demonstr
qualiti
ldp
valid
perform
accord
clia
exampl
also
serv
highlight
qualiti
effort
interlaboratori
comparison
take
place
ldp
offer
laboratori
clinic
use
activ
data
often
unknown
clinician
util
test
servic
tabl
provid
guid
exampl
includ
summar
impact
assay
along
key
point
util
enceph
seriou
complic
herp
simplex
viru
hsv
infect
rare
hsv
commonli
includ
among
caus
viral
enceph
sinc
hsv
infect
treat
effect
acyclovir
critic
rapidli
accur
establish
diagnosi
initi
treatment
reduc
morbid
mortal
cultur
cerebrospin
fluid
csf
insensit
diagnosi
hsv
enceph
brain
biopsi
invas
procedur
signific
morbid
histor
requir
make
diagnosi
result
avail
day
afterward
sever
studi
demonstr
detect
viral
dna
polymeras
chain
reaction
pcr
use
csf
sampl
perform
equival
brain
biopsi
includ
landmark
studi
given
eas
collect
csf
sampl
lower
risk
complic
lower
cost
speed
result
pcr
becam
standard
care
diagnos
hsv
cn
infect
ldp
use
nearli
year
first
fdaclear
pcr
test
diagnosi
hsv
enceph
becam
avail
second
test
clear
laboratorydevelop
test
procedur
dramat
improv
qualiti
care
mani
patient
continu
use
success
today
clear
test
limit
requir
specif
instrument
standard
mani
laboratori
addit
one
test
highli
multiplex
may
appropri
clinic
situat
herp
simplex
viru
also
caus
infect
neonat
frequenc
deliveri
unit
state
infect
acquir
exposur
matern
genit
secret
present
neonat
hsv
vari
includ
skin
eye
mouth
infect
enceph
dissemin
diseas
case
rapid
diagnosi
need
prevent
morbid
sequela
enceph
diagnosi
enceph
made
via
pcr
csf
sampl
test
plasma
serum
critic
diagnos
dissemin
diseas
abil
use
plasma
serum
import
may
difficult
obtain
enough
csf
newborn
assess
diagnos
differenti
although
fdaclear
assay
test
csf
hsv
assay
clear
test
serum
plasma
laboratorydevelop
test
procedur
continu
play
critic
role
diagnosi
manag
dissemin
hsv
infect
newborn
addit
ldp
perform
high
degre
accuraci
interlaboratori
agreement
blind
pt
sampl
distribut
laboratori
part
cap
pt
survey
analysi
hsv
correctli
identifi
identifi
hsv
note
subtyp
overal
accuraci
obtain
previou
profici
survey
show
similar
result
sampl
contain
laboratori
use
ldp
bk
viru
infect
common
seropreval
adult
popul
primari
infect
viru
colon
renal
urinari
tract
healthi
individu
occasion
shed
viru
urin
without
consequ
howev
renal
transplant
recipi
bk
viru
major
caus
polyomavirusassoci
nephropathi
pvan
put
kidney
transplant
patient
risk
prematur
allograft
failur
given
lack
effect
antivir
therapi
bk
viru
key
prevent
allograft
loss
identifi
atrisk
renal
transplant
recipi
earli
reduc
immunosuppress
therapi
pvan
develop
reduct
immunosuppress
therapi
help
control
viral
replic
case
prevent
develop
pvan
critic
balanc
much
immunosuppress
therapi
lead
pvan
littl
immunosuppress
caus
reject
abil
monitor
bk
viru
level
blood
allow
inform
clinic
decis
studi
shown
monitor
patient
viral
load
test
first
year
transplant
dramat
reduc
develop
pvan
consensu
guidelin
recommend
screen
bk
replic
perform
least
everi
month
first
year
posttranspl
annual
fifth
year
posttranspl
plasma
viral
load
valu
rise
threshold
copiesml
renal
biopsi
may
perform
assess
pvan
immunosuppress
therapi
reduc
base
result
biopsi
viral
load
test
also
done
increas
serum
creatinin
level
bk
viru
aid
distinguish
reject
pvan
although
bk
viral
load
test
standard
care
sever
year
use
transplant
center
across
countri
fdaclear
fdaapprov
test
avail
test
perform
use
ldp
ldp
avail
case
pvan
would
identifi
promptli
lead
neg
patient
outcom
allograft
loss
reject
cytomegaloviru
cmv
caus
wide
rang
complic
among
solid
organ
transplant
hematopoiet
stem
cell
transplant
recipi
well
immunocompromis
patient
cytomegaloviru
high
seropreval
larg
number
transplant
patient
experi
reactiv
primari
infect
probabl
increas
base
pretranspl
serostatu
sever
pretranspl
condit
allograft
related
although
infect
subclin
high
increas
viral
load
signal
increas
risk
symptomat
diseas
rang
rel
mild
constitut
symptom
sever
endorgan
infect
potenti
fatal
dissemin
diseas
preemptiv
therapi
highrisk
patient
base
detect
increas
cmv
load
peripher
blood
shown
effect
howev
first
fdaapprov
ivd
test
appear
market
interven
year
laboratorydevelop
assay
play
critic
role
bridg
gap
presenc
method
adopt
across
countri
enabl
routin
use
cmv
screen
asymptomat
patient
transplant
center
soon
data
support
util
avail
method
like
save
mani
live
year
support
earli
diagnosi
preemptiv
treatment
strategi
assess
therapeut
treatment
efficaci
widespread
use
ldp
cmv
quantit
method
produc
gener
transplant
physician
comfort
use
method
chang
epidemiolog
posttranspl
cmv
diseas
markedli
reduc
incid
earli
diseas
patient
year
ldp
use
numer
studi
focus
continu
improv
optim
method
includ
develop
intern
quantit
standard
abil
rapidli
incorpor
advanc
technolog
includ
advent
realtim
quantit
method
demonstr
improv
sensit
perform
characterist
test
time
data
accumul
throughout
experi
inform
develop
first
commerci
avail
cmv
ivd
assay
fact
absenc
ldp
vast
clinic
laboratori
experi
provid
like
would
delay
avail
commerci
method
perform
characterist
taken
longer
optim
today
level
human
papilloma
viru
hpv
caus
agent
genit
wart
implic
develop
cervic
cancer
hpv
genotyp
describ
approxim
capabl
infect
human
genit
tract
rel
known
caus
cervic
cancer
malign
identifi
genotyp
today
assay
fda
approv
detect
highrisk
hpv
genotyp
strain
cervic
specimen
test
routin
use
confirm
presenc
hpv
infect
screen
cervic
cancer
refer
case
indetermin
cytolog
examin
past
decad
rise
oropharyng
squamou
cell
cancer
primarili
caucasian
male
limit
alcohol
tobacco
exposur
describ
unexpectedli
investig
discov
frequent
presenc
highrisk
hpv
genotyp
strain
lesion
human
papilloma
virusposit
head
neck
cancer
biolog
distinct
hpvneg
diseas
patient
hpvdriven
tumor
significantli
better
prognosi
includ
respons
chemoradi
therapi
overal
surviv
compar
hpvneg
patient
therefor
test
head
neck
cancer
specimen
highrisk
hpv
genotyp
becom
standard
care
use
guid
treatment
howev
hpv
test
fda
approv
cervic
specimen
approv
head
neck
cancer
leav
critic
gap
patient
care
clinic
laboratori
thu
develop
new
assay
modifi
exist
fdaapprov
one
detect
highrisk
hpv
genotyp
head
neck
cancer
specimen
inclus
patient
sever
clinic
trial
base
ldp
wwwclinicaltrialsgov
access
april
without
laboratorydevelop
test
patient
head
neck
cancer
benefit
person
treatment
strategi
clinic
laboratori
must
highli
vigil
infecti
diseas
outbreak
sinc
like
first
recov
pathogen
recogn
potenti
outbreak
recent
exampl
emerg
reemerg
pathogen
caus
substanti
human
morbid
mortal
includ
avian
influenza
viru
bird
flu
chikungunya
viru
ebola
viru
middl
eastern
respiratori
syndrom
viru
sever
acut
respiratori
syndrom
viru
zika
viru
time
emerg
fdaapprov
test
avail
detect
pathogen
respons
mani
clinic
laboratori
develop
valid
implement
ldp
need
care
patient
institut
assay
base
extens
data
set
report
peerreview
journal
support
qualiti
claim
sinc
perform
characterist
analyt
sensit
limit
detect
may
vari
differ
assay
design
recent
discuss
sever
differ
zika
viru
test
sort
collabor
effort
essenti
mani
case
laboratori
lead
effort
collabor
one
anoth
share
valid
materi
perform
interlaboratori
comparison
exchang
blind
test
sampl
http
wwwusatodaycomstori
access
april
perhap
ideal
urgent
need
integr
coordin
mechan
rapid
diagnosi
novel
infecti
agent
incorpor
public
health
hospit
laboratori
recent
emerg
zika
viru
link
sever
birth
defect
underscor
need
clinic
laboratori
rapid
access
diagnost
tool
secretari
health
human
servic
declar
zika
viru
public
health
emerg
first
fda
emerg
use
author
zika
viru
test
grant
test
avail
public
health
laboratori
system
hospit
laboratori
front
line
patient
care
http
wwwfe
zationofemergencyuseofaninvitrodiagnosticdevicefordiagnosisofzikaviru
access
april
result
public
health
system
quickli
becam
overwhelm
past
outbreak
influenza
mani
area
turnaround
time
zika
viru
test
exceed
week
http
access
april
http
access
april
http
wwwmiamih
access
april
delay
critic
impact
patient
care
particularli
pregnant
women
possibl
affect
fetus
comparison
mani
hospitalbas
nation
refer
laboratori
abl
report
result
within
hour
http
access
april
http
idapregnanthtml
access
april
exampl
miamidad
florida
peopl
confirm
zika
posit
viru
circul
local
mosquito
popul
public
health
laboratori
system
encount
backlog
nearli
untest
specimen
http
wwwmiamiheraldcomnewshealthcarearti
access
april
diagnost
assay
zika
emerg
pathogen
continu
evolv
clear
rapid
identif
pathogen
outbreak
facilit
rapid
treatment
appropri
isol
patient
lead
improv
patient
outcom
potenti
slow
spread
infect
influenza
http
wwwcdcgovfluprofessionalsdiagnosismolecu
larassayshtm
access
april
implement
first
rapid
diagnost
test
influenza
directli
associ
reduc
length
hospit
stay
decreas
mortal
reduc
cost
access
diagnost
test
earli
cours
outbreak
hospit
laboratori
posit
public
health
impact
kra
gene
encod
gtpase
critic
signal
transduct
known
mutat
wide
rang
tumor
type
landmark
studi
present
american
societi
clinic
oncolog
asco
meet
demonstr
patient
metastat
colorect
cancer
harbor
mutat
kra
fail
respond
target
therapi
cetuximab
time
clinic
test
kra
mutat
avail
molecular
patholog
laboratori
work
quickli
fill
need
defin
best
analyt
approach
ensur
test
result
done
one
laboratori
match
done
anoth
within
month
laboratori
abl
offer
fulli
valid
kra
assay
work
reliabl
safe
patient
care
clia
valid
data
collect
laboratori
subject
ongo
peer
review
laboratori
particip
ongo
pt
demonstr
consist
assay
qualiti
asco
nation
comprehens
cancer
network
nccn
recommend
mutat
profil
kra
exon
institut
antiepiderm
growth
factor
receptor
egfr
therapi
patient
metastat
colorect
cancer
becam
standard
care
assess
formalinfix
paraffinembed
tumor
tissu
patient
metastat
colon
cancer
kra
mutat
statu
year
later
fda
clear
qiagen
therascreen
kra
test
design
detect
presenc
mutat
kra
gene
colorect
cancer
time
new
data
demonstr
kra
analysi
alon
enough
mutat
analysi
gene
necessari
fdaapprov
assay
alreadi
inadequ
patient
test
compliant
nation
treatment
guidelin
without
ldp
estim
patient
nonexon
kra
mutat
would
overtr
expens
antiegfr
therapi
use
ldp
thu
persist
clinic
practic
provid
patient
complet
inform
guid
treatment
cap
mail
laboratori
report
result
test
blind
proficiencytest
specimen
specimen
contain
recur
somat
mutat
kra
exon
v
accept
respons
report
laboratori
mutat
vast
major
report
laboratori
util
ldp
kra
ra
famili
gene
mutat
analysi
also
critic
manag
patient
nonsmallcel
lung
cancer
nsclc
tumor
fda
approv
kit
occur
ldp
offlabel
use
kit
requir
braf
belong
famili
serinethreonin
protein
kinas
particip
signal
transduct
cascad
involv
ra
raf
mek
erk
famili
member
pathway
import
regul
normal
cell
prolifer
differenti
activ
mutat
braf
lead
increas
prolifer
prolong
cell
surviv
varieti
tumor
type
laboratori
typic
test
braf
mutat
lowgrad
glioma
diagnosi
colorect
cancer
establish
sporad
origin
msih
tumor
respons
antiegfr
therapi
hairi
cell
leukemia
diagnosi
lung
adenocarcinoma
predict
respons
therapi
thyroid
cancer
preoper
detect
thyroid
cancer
fna
sampl
prognosi
papillari
thyroid
carcinoma
melanoma
predict
respons
braf
kinas
inhibitor
one
indic
malign
melanoma
fdaapprov
companion
diagnost
avail
vemurafenib
zelboraf
kinas
inhibitor
indic
treatment
patient
unresect
metastat
melanoma
braf
mutat
dabrafenib
tafinlar
kinas
inhibitor
indic
singl
agent
treatment
patient
unresect
metastat
melanoma
braf
mutat
combin
trametinib
mekinist
treatment
patient
unresect
metastat
melanoma
braf
mutat
wwwfdagov
access
april
coba
braf
mutat
test
roch
molecular
system
pleasanton
ca
usa
sporad
cross
react
braf
braf
mutat
thu
neither
sensit
braf
mutat
specif
braf
mutat
confound
accur
outcom
evalu
prevent
use
select
patient
tafinlar
therapi
thxid
braf
kit
biomerieux
boston
usa
detect
braf
braf
mutat
braf
mutat
necessari
distinguish
altern
therapeut
option
singl
agent
vs
combin
therapi
import
note
increas
cell
prolifer
seen
tumor
treat
braf
inhibitor
normal
braf
therefor
import
identifi
braf
activ
mutat
assist
select
appropri
therapi
fdaapprov
assay
therefor
adequ
current
clinic
need
european
multicent
studi
consecut
tumor
sampl
histolog
proven
melanoma
tumor
tissu
assess
braf
mutat
statu
coba
system
varieti
laboratori
develop
procedur
test
concord
sampl
discord
among
discord
case
invalid
result
sampl
coba
ldp
sampl
braf
mutat
detect
ldp
coba
mutat
test
r
mutat
contain
tumor
cell
sampl
braf
mutat
detect
coba
ldp
confirm
retest
mutat
consid
invalid
result
studi
document
similar
result
perform
braf
ldp
ivd
data
gather
cap
pt
program
cap
profici
survey
laboratori
report
detect
braf
mutat
varieti
analyt
method
two
wellcharacter
specimen
profici
test
contain
braf
allel
laboratori
correctli
report
mutat
major
laboratori
use
ldp
current
avail
braf
mutat
test
approv
use
tumor
type
mention
use
exist
ivd
test
would
constitut
offlabel
use
henc
ldp
microsatellit
instabl
presenc
hypermut
repetit
dna
sequenc
result
impair
dna
mismatch
repair
microsatellit
instabl
inherit
acquir
featur
tumor
microsatellit
instabl
occur
approxim
colorect
carcinoma
consist
featur
colorect
tumor
patient
lynch
syndrom
tumor
classifi
show
high
level
msi
msih
phenotyp
microsatellit
marker
exhibit
instabl
microsatellitest
phenotyp
none
marker
show
instabl
msilow
phenotyp
less
marker
show
instabl
studi
confirm
appropri
cutoff
determin
msih
phenotyp
find
instabl
marker
test
find
msih
phenotyp
consist
presenc
defect
dna
mmr
tumor
find
msih
phenotyp
crc
increas
likelihood
patient
ls
specif
ls
definit
establish
diagnosi
ls
requir
find
pathogen
germlin
mutat
one
dna
mmr
gene
addit
test
offer
determin
whether
patient
msih
crc
like
ls
includ
test
tumor
dna
mmr
protein
express
use
ihc
braf
point
mutat
analysi
sinc
brafmut
msih
colorect
carcinoma
known
sporad
mmr
gene
mutat
promot
hypermethyl
studi
shown
msih
phenotyp
favor
independ
prognost
indic
patient
crc
addit
report
indic
msih
tumor
may
respons
therapi
recent
draft
guidelin
develop
collabor
profession
societi
recommend
defici
mismatch
repairmicrosatellit
instabl
test
must
perform
colorect
cancer
prognost
stratif
identif
patient
lynch
syndrom
although
numer
laboratori
offer
msi
test
use
ldp
current
fdaapprov
test
evalu
microsatellit
instabl
summari
cap
pt
result
demonstr
excel
perform
laboratori
particip
msi
profici
survey
good
perform
laboratori
year
may
partli
due
educ
natur
cap
pt
provid
laboratori
extern
mechan
monitor
qualiti
statu
test
epiderm
growth
factor
receptor
membranebound
tyrosin
kinas
activ
sever
signal
pathway
known
alter
human
cancer
includ
nsclc
nonsmal
cell
lung
cancer
tumor
egfractiv
mutat
respons
gefitinib
erlotinib
small
molecul
tyrosin
kinas
inhibitor
egfr
fda
approv
antiegfr
therapi
base
clinic
trial
outcom
data
result
need
clinic
laboratori
test
tumor
tissu
egfrsensit
mutat
order
patient
elig
treatment
fdaapprov
companion
diagnost
test
market
clialicens
laboratori
develop
valid
ldp
test
common
egfr
mutat
earli
fda
follow
approv
roch
coba
egfr
mutat
test
along
qiagen
therascreen
egfr
rgq
kit
assay
test
exon
delet
exon
point
mutat
note
test
approv
specif
therapeut
indic
specimen
type
new
drug
becam
avail
approv
new
claim
need
laboratorydevelop
procedur
continu
method
choic
due
limit
claim
made
fdaapprov
assay
perform
characterist
includ
type
mutat
detect
clinic
laboratori
particip
twiceyearli
profici
test
challeng
unknown
sampl
must
analyz
report
result
grade
compar
laboratori
perform
test
cap
profici
test
laboratori
report
result
test
unknown
proficiencytest
specimen
late
specimen
con
note
laboratori
test
certain
mutat
henc
denomin
often
less
patient
treat
new
target
antiegfr
therapi
began
relaps
studi
reveal
egfr
harbor
sensit
resist
mutat
clia
laboratori
demonstr
abil
detect
mutat
egfr
gene
well
gene
use
ng
assay
sequenc
panel
cancerrel
gene
panel
approach
allow
laboratori
provid
oncologist
comprehens
profil
tumor
use
costeffect
technolog
make
maxim
use
small
tissu
sampl
thu
make
treatment
strategi
effect
addit
time
save
test
broader
panel
gene
target
result
better
outcom
patient
well
fewer
advers
drug
reaction
payer
cost
save
approach
versu
algorithmbas
test
singl
gene
assay
signific
current
fdaapprov
sequenc
assay
egfr
mutat
statu
ldp
sole
use
detect
mutat
defin
therapi
select
complex
cancer
biolog
everevolv
therapeut
approach
manag
patient
cancer
often
requir
expand
knowledg
tumor
beyond
singlegen
mutat
statu
past
sever
year
laboratori
abil
multiplex
test
sever
gene
genet
variant
limit
avail
technolog
nextgener
sequenc
massiv
parallel
sequenc
allow
laboratori
provid
comprehens
genom
profil
tumor
cell
singl
assay
previou
method
abil
detect
numer
mutat
multipl
gene
result
inform
allow
oncologist
develop
accur
treatment
strategi
includ
therapi
select
base
respons
tumor
profil
select
base
presenc
resist
mutat
instrument
thermo
fisher
thermo
fisher
lifetechnolog
carlsbad
ca
usa
illumina
illumina
san
diego
ca
usa
person
genom
machin
pgm
miseq
made
ng
suitabl
routin
clinic
laboratori
test
miseq
dx
obtain
fda
approv
despit
approv
routin
use
ng
ldp
set
current
fdaapprov
ng
test
applic
oncolog
although
mani
drug
packag
insert
requir
allud
use
companion
diagnost
elig
companion
diagnost
test
fda
approv
none
use
ng
technolog
ldp
clinic
laboratori
requir
demonstr
rigor
perform
criteria
wetbench
test
analysi
pipelin
ensur
test
function
properli
intend
clinic
purpos
ng
test
therapeut
select
cancer
consist
panel
gene
rang
gene
test
design
detect
hotspot
known
mutat
gene
sequenc
entir
code
region
gene
sequenc
entir
gene
end
result
comprehens
profil
tumor
genom
use
tailor
therapi
individu
patient
although
ng
assay
cost
singlegen
assay
cost
per
gene
sequenc
dramat
reduc
result
cost
save
use
multipl
singlegen
test
furthermor
ng
panel
appli
small
specimen
sampl
use
littl
ng
input
dna
depend
analyt
platform
util
sinc
evalu
therapeut
biomark
usual
need
set
advanc
diseas
patient
often
limit
tissu
sampl
avail
test
ng
assay
allow
much
extens
genom
inform
obtain
compar
singlegen
assay
requir
dna
input
compar
entir
ng
panel
total
laboratori
recent
particip
capsponsor
profici
assess
ng
cancer
panel
test
data
collect
gene
mutat
alk
braf
egfr
kit
kra
nra
genotyp
call
across
spectrum
mutat
test
call
concordantli
unpublish
data
ldp
field
oncolog
greater
impact
patient
care
quantit
rna
chronic
myelogen
leukemia
cml
one
first
arguabl
success
molecularli
target
cancer
therapi
tyrosin
kinas
inhibitor
imatinib
fdaapprov
earli
day
target
therapi
long
advent
fdaapprov
companion
diagnost
ubiquit
obviou
method
determin
efficaci
novel
leukemia
treatment
directli
quantit
target
inhibitor
drug
name
cancer
cellspecif
fusion
gene
reduct
posttreat
rna
level
measur
sensit
laboratorydevelop
pcrbase
method
shown
best
avail
test
predict
therapeut
respons
longterm
progressionfre
surviv
tkitreat
patient
cml
consensu
oncolog
practic
guidelin
unit
state
nccn
europ
eln
go
back
least
decad
univers
recommend
tkitreat
patient
cml
serial
monitor
laboratorydevelop
rtpcr
blood
test
least
everi
month
lifelong
cours
tki
therapi
nccn
eln
guidelin
also
long
recommend
serial
rna
test
directli
inform
appropri
dose
tki
overcom
develop
resist
also
therapeut
switch
one
tki
anoth
depend
drug
known
resist
profil
directli
support
optim
therapeut
decisionmak
routin
care
patient
cml
clinic
laboratori
offer
accur
sensit
pcrbase
laboratorydevelop
procedur
least
last
year
recogn
standard
ldp
necessari
promot
uniform
therapeut
decisionmak
laboratori
commun
undertook
extens
multiyear
project
creat
standard
intern
scale
measur
messeng
rna
followup
effort
result
creation
world
health
organizationrecogn
panel
refer
materi
directli
link
subsequ
creation
secondari
iscalibr
refer
materi
could
use
routin
daili
qc
clinic
laboratori
recogn
addit
need
pt
cap
offer
semiannu
pt
survey
least
year
progress
increas
number
particip
laboratori
proof
nearunivers
recognit
assay
standard
approxim
accredit
laboratori
report
pcr
result
use
standard
cap
survey
confirm
excel
interlaboratori
precis
laboratori
report
result
within
intern
acknowledg
accept
toler
limit
log
report
sampl
approxim
reduct
pretreat
level
primari
drive
forc
behind
remark
increas
longev
qualiti
life
patient
cml
past
year
doubt
avail
noveltarget
tki
therapi
becom
paradigm
personalizedprecis
cancer
medicin
program
coupl
parallel
effort
laboratori
commun
toward
build
improv
standard
accur
precis
sensit
laboratorydevelop
test
note
target
therapi
program
cml
occur
entir
without
avail
fdaapprov
bcrabl
diagnost
reagent
becom
avail
fdaapprov
assay
base
upon
develop
clinic
laboratori
approv
diagnosi
cml
cover
spectrum
breakpoint
occur
diseas
groundbreak
first
year
target
cancer
therapi
era
laboratori
commun
prohibit
provid
highqual
standard
ldpbase
test
exist
clia
guidelin
neg
consequ
patient
care
past
futur
would
substanti
fragil
x
fx
syndrom
one
common
inherit
caus
intellectu
disabl
caus
molecular
mechan
expans
cgg
repeat
region
regulatori
region
fmrp
gene
cgg
repeat
expand
beyond
approxim
cgg
repeat
gene
methyl
silenc
laboratori
test
fx
includ
size
number
repeat
well
methyl
analysi
avail
clinic
diagnost
carrier
statu
test
year
american
colleg
medic
genet
genom
acmg
publish
practic
guidelin
appropri
test
order
first
tier
test
individu
famili
xlink
inherit
pattern
intellectu
disabl
suspect
expand
fx
allel
identifi
famili
member
test
identifi
premut
carrier
risk
affect
offspr
prenat
fetal
preimplant
genet
diagnost
test
avail
known
fx
carrier
accord
genet
test
registri
laboratori
unit
state
offer
test
fx
http
wwwncbinlm
nihgovgtr
access
current
fx
test
perform
ldp
fdaclear
assay
avail
pcr
primer
southern
blot
reagent
avail
commerci
analytespecif
reagent
asr
investig
use
clinic
laboratori
use
commerci
reagent
design
primer
probe
combin
intern
develop
assay
establish
perform
characterist
acmg
publish
standard
guidelin
clinic
laboratori
perform
test
refer
materi
standard
size
develop
genet
test
refer
materi
program
sponsor
center
diseas
control
prevent
cdc
nation
institut
standard
technolog
http
wwwnistgovnod
access
novemb
world
health
organ
profici
test
cap
demonstr
excel
perform
clinic
laboratori
highcomplex
ldp
genet
basi
mani
human
diseas
becam
appar
sequencebas
diagnost
test
implement
way
provid
definit
diagnos
patient
famili
mani
laboratori
began
offer
sequencebas
test
herit
disord
use
varieti
mutationscan
techniqu
singlestrand
conform
polymorph
denatur
hplc
mlpa
other
sangerbas
sequenc
gold
standard
despit
slow
expens
multigen
natur
disord
made
sequenc
approach
challeng
due
sheer
number
gene
size
sequenc
requir
analysi
recent
year
howev
test
convert
ng
offer
signific
advantag
term
analyt
capabl
qualiti
speed
cost
repetit
sequenc
read
singl
region
ensur
enhanc
level
qualiti
ng
assay
design
interrog
anyth
small
larg
gene
panel
whole
exom
beyond
depend
clinic
need
address
consensu
guidelin
ng
assay
develop
multipl
profession
societi
address
develop
valid
qualiti
control
assay
cap
develop
inspect
checklist
laboratori
perform
ng
detect
somat
mutat
cancer
well
germlin
mutat
caus
herit
diseas
progress
also
made
plan
product
refer
materi
profici
sampl
togeth
practic
resourc
yield
laboratorydevelop
assay
demonstr
meet
qualiti
level
need
patient
care
addit
continu
qualiti
assess
wet
laboratori
procedur
ongo
nation
intern
effort
share
data
construct
maintain
uptod
curat
databas
variant
interpret
critic
qualiti
care
new
mutat
variant
detect
interpret
assess
clinic
impact
includ
determin
clinic
import
variant
undetermin
signific
critic
rapid
gener
genom
data
disorgan
data
share
lack
standard
creat
challeng
consist
approach
clinic
sequenc
interpret
need
along
central
openli
access
databas
sequenc
clinic
inform
recognit
urgent
need
uptod
variant
classif
resourc
acmg
associ
molecular
patholog
releas
landmark
guidanc
document
implement
us
intern
laboratori
addit
resourc
outlin
includ
ncbi
clinvar
databas
http
wwwncbinlmnihgovclinvar
quickli
becom
valuabl
central
resourc
clinic
classifi
variant
clinic
genom
resourc
clingen
wwwclinicalgenomeorg
serv
central
site
manag
genom
knowledg
surround
gene
variant
exom
genom
sequenc
increasingli
implement
guidanc
issu
acmgg
deal
incident
identif
variant
socal
action
gene
patient
test
unrel
condit
addit
qualiti
assess
focus
informat
pipelin
variant
interpret
could
effect
util
sequenc
data
set
recent
outlin
genet
patholog
commun
increasingli
embrac
data
share
lead
need
improv
diverg
interpret
gene
sequenc
variant
interpret
task
would
beyond
scope
fda
approv
kit
clia
oversight
ldp
critic
impact
patient
care
base
genom
inform
nextgener
sequenc
analysi
varieti
gene
panel
becom
routin
clinic
care
posit
impact
diagnosi
treatment
patient
famili
complex
syndrom
disord
exampl
common
clinic
set
gene
panel
test
potenti
germlin
mutat
provid
along
inform
clinic
set
potenti
benefit
also
challeng
util
approach
inherit
cardiomyopathi
common
disord
includ
hypertroph
cardiomyopathi
hcm
dilat
cardiomyopathi
arrhythmogen
right
ventricular
cardiomyopathi
restrict
cardiomyopathi
sever
characterist
inherit
cardiomyopathi
provid
compel
reason
genet
test
includ
substanti
genet
compon
detect
rate
current
rang
long
presymptomat
phase
acut
diseas
onset
typic
adolesc
predisposit
sudden
cardiac
death
scd
first
present
sign
frequent
heartbreak
public
follow
case
sudden
death
competit
athlet
brought
diseas
public
attent
recent
studi
show
scd
case
due
underli
unrecogn
inherit
cardiomyopathi
import
herit
abnorm
underscor
fact
nearli
third
gene
acmg
recommend
return
result
regardless
test
indic
made
cardiomyopathi
gene
disord
heterogen
lead
clinic
diagnost
uncertainti
error
henc
larg
multigen
panel
particularli
use
cover
spectrum
gene
may
caus
clinic
disord
importantli
identif
pathogen
variant
affect
individu
inform
medic
manag
famili
member
identifi
risk
earli
also
releas
neg
individu
clinic
screen
genet
test
also
identifi
phenocopi
fabri
diseas
masquerad
isol
hcm
fabri
diseas
rare
diseasemodifi
treatment
avail
therefor
genet
test
provid
essenti
clinic
inform
patient
epilepsi
common
disord
central
nervou
system
character
period
loss
conscious
without
convuls
associ
abnorm
electr
activ
brain
significantli
affect
qualiti
life
major
psycholog
socioeconom
consequ
estim
million
peopl
epilepsi
worldwid
estim
peopl
unit
state
develop
epilepsi
point
lifetim
signific
proport
case
show
famili
distribut
increas
risk
epilepsi
famili
histori
prime
requir
success
manag
epilepsi
complet
diagnosi
select
optim
treatment
benefit
patient
develop
epilepsi
may
involv
multipl
gene
abnorm
gene
abnorm
concert
environment
trigger
gene
shown
associ
epilepsi
precis
genet
diagnosi
help
decid
accur
treatment
followup
evalu
gene
implic
epilepsi
effici
accomplish
use
ng
panel
provid
accur
inform
physician
treatment
plan
nextgener
sequenc
assay
perform
ldp
clia
exampl
one
gene
caus
dravet
syndrom
success
treat
import
avoid
treatment
sodium
channel
blocker
worsen
seizur
dravet
syndrom
includ
phenytoin
dilantin
fosphenytoin
cerebyx
prodilantin
carbamazepin
tegretol
medic
ongo
research
reveal
new
gene
mutat
relev
diseas
import
classifi
newli
found
variant
quickli
accur
open
access
new
inform
consensu
effort
defin
standard
classif
report
variant
vuss
critic
ensur
patient
get
uptod
complet
inform
genom
test
anoth
exampl
recent
discov
gene
tbckrelat
epilepsi
tbckrelat
intellectu
disabl
syndrom
rare
development
delay
hypotonia
seizur
children
lower
level
tbck
protein
slower
cell
mtor
signal
improv
addit
leucin
may
provid
futur
therapeut
option
import
clinic
laboratori
adapt
ng
panel
incorpor
new
target
clinic
util
establish
neuromuscular
diseas
nmd
refer
collect
mani
disord
affect
peripher
nervou
system
either
impair
proper
develop
function
muscl
damag
associ
nerv
neuromuscular
junction
muscular
dystrophi
form
major
inherit
nmd
share
clinic
genet
patholog
characterist
includ
muscl
degener
wast
progress
muscl
weak
hypotonia
variabl
elev
serum
creatin
kinas
level
cardiac
involv
often
present
account
high
morbid
mortal
differ
genet
defin
type
muscular
dystrophi
categor
base
age
onset
specif
muscl
involv
common
characterist
clinic
featur
congenit
muscular
dystrophi
limbgirdl
muscular
dystrophi
major
subgroup
genet
heterogen
mani
new
gene
implic
recent
year
lack
pathognomon
sign
specif
biochem
marker
presenc
high
phenotyp
overlap
form
nmd
make
diagnosi
difficult
molecular
assess
critic
establish
diagnosi
also
allow
particip
clinic
trial
therapeut
treatment
design
specif
set
variant
variant
type
extens
diagnost
workup
involv
protein
studi
muscl
biopsi
may
use
narrow
number
singl
gene
test
mani
patient
never
specif
diagnos
comprehens
approach
expedit
molecular
diagnosi
includ
ngsbase
panel
test
sequenc
analysi
diseaseassoci
gene
singl
analysi
herit
cancer
panel
genom
test
famili
cancer
syndrom
becom
routin
past
decad
approxim
herit
cancer
syndrom
recogn
caus
cancer
although
famili
breast
cancer
perhap
becom
publicli
known
exampl
test
gene
inherit
cancer
syndrom
may
includ
ng
multigen
panel
patient
carri
germlin
mutat
lifetim
risk
breast
cancer
us
prevent
task
forc
recommend
test
women
famili
member
breast
ovarian
fallopian
tube
periton
cancer
meet
criteria
numer
studi
demonstr
psychosoci
benefit
genet
counsel
test
patient
carri
germlin
mutat
surgic
intervent
may
significantli
reduc
risk
cancer
death
contralater
mastectomi
shown
reduc
risk
death
carrier
prophylact
salpingooophorectomi
shown
dramat
reduc
mortal
due
ovarian
cancer
breast
cancer
mutat
carrier
similarli
identif
lynch
syndrom
mutat
permit
surveil
lead
earlier
detect
mark
improv
surviv
patient
develop
colorect
endometri
ovarian
cancer
although
decad
pass
sinc
sequencebas
analysi
highpenetr
cancer
gene
perform
laboratorydevelop
procedur
avail
countless
patient
famili
benefit
avail
ldp
epidermolysi
bullosa
eb
inherit
skin
connect
tissu
diseas
caus
skin
oral
blister
mild
trauma
http
wwwniamsnihgovhealthinfoepidermolysi
bullosaepidermolysisbullosaff
access
novemb
sever
disord
depend
layer
skin
tissu
separ
occur
approxim
patient
biopsyproven
eb
mutat
gene
known
caus
disord
http
wwwniamsnihgovhealthinfoepid
molysisbullosaepidermolysisbullosaff
access
novemb
knowledg
specif
gene
direct
therapi
provid
reproduct
option
famili
mani
year
possibl
sequenc
suspect
gene
one
one
take
month
year
research
basi
recent
advent
ng
technolog
small
number
clinic
laboratori
step
develop
rapid
multigen
ng
approach
provid
answer
quickli
time
make
treatment
decis
well
provid
carrier
prenat
test
atrisk
famili
new
candid
gene
identifi
ng
valid
offer
clinic
test
clia
valid
data
collect
laboratori
subject
ongo
peer
review
laboratori
particip
ongo
pt
demonstr
assay
qualiti
diseas
rare
children
born
eb
annual
cost
bring
test
fda
approv
prohibit
without
avail
ldp
patient
famili
affect
diseas
would
go
without
specif
diagnos
unabl
enrol
genemut
specif
therapi
current
develop
least
pharmaceut
compani
academ
center
http
wwwdebraorgresearchtri
access
novemb
control
reproduct
live
wholeexom
sequenc
we
involv
evalu
code
region
human
gene
search
underli
molecular
caus
undiagnos
presum
genet
disord
test
use
patient
alreadi
undergon
extens
genet
diagnost
test
exhaust
limit
fda
ldp
singlegen
test
case
costand
timeeffect
start
we
wholeexom
sequenc
use
socal
diagnost
odyssey
patient
high
diagnost
yield
patient
studi
yield
diagnosi
test
highli
complex
involv
captur
relev
dna
segment
sequenc
segment
bioinformat
approach
sequenc
align
identif
variant
differ
patient
dna
refer
interpret
identifi
variant
report
gener
clia
nysdoh
technic
valid
data
collect
laboratori
prior
offer
we
requir
laboratori
particip
ongo
pt
cap
sampl
exchang
demonstr
assay
qualiti
cuttingedg
scienc
medic
practic
captur
sequenc
technolog
bioinformat
interpret
tool
evolv
fast
pace
provid
best
servic
patient
laboratori
must
frequent
updat
revalid
offer
new
servic
wholeexom
sequenc
offer
ldp
laboratori
extens
experi
genet
test
time
delay
involv
bring
test
frequent
modif
fda
prohibit
test
serv
rare
diseas
commun
reimburs
limit
lack
price
specif
cpt
code
cost
bring
we
fda
approv
would
major
deterr
innov
would
slow
like
sever
laboratori
would
remov
test
test
menu
affect
individu
unit
state
huntington
diseas
hd
fall
categori
rare
orphan
disord
given
limit
market
commerci
genet
test
platform
develop
submit
fda
review
rel
small
number
laboratori
offer
diagnost
predict
presymptomat
test
disord
must
therefor
reli
entir
ldp
without
patient
hd
atrisk
rel
would
access
test
diagnosi
despit
characterist
clinic
featur
movement
disord
chorea
along
intellectu
declin
lack
prevent
cur
treatment
hd
genet
test
wide
reli
upon
hd
famili
physician
onset
symptom
often
insidi
nonspecif
definit
earli
diagnosi
accomplish
dna
level
presymptomat
test
offer
adult
offspr
patient
hd
risk
inherit
autosom
domin
diseas
accomplish
use
ldp
allow
crucial
lifeplan
decis
educ
pursuit
career
choic
marriag
whether
children
afford
abil
pursu
prenat
diagnosi
whether
begin
plan
inevit
disabl
without
test
atrisk
rel
estim
unit
state
would
lead
live
anxious
wait
symptom
begin
half
actual
risk
inherit
mutant
gene
affect
parent
although
atrisk
rel
choos
avail
predict
test
mani
opt
test
credit
free
year
obsess
uncertainti
result
afford
affect
patient
opportun
enrol
clinic
trial
involv
drug
neuron
stem
cell
aim
prevent
delay
onset
symptom
although
studi
still
earli
phase
outcom
data
yet
avail
give
patient
hope
futur
perhap
also
futur
patient
given
mechan
gradual
neuron
cell
death
basal
ganglia
stand
reason
earlier
intervent
initiatedid
presymptomat
stageth
higher
chanc
success
huntington
diseas
one
trinucleotid
repeat
disord
caus
expans
tandem
repeat
cag
first
intron
huntingtin
htt
gene
contrast
fx
syndrom
trinucleotid
repeat
disord
differ
mutat
nonmut
repeat
length
littl
singl
repeat
ie
nucleotid
thu
extrem
care
requir
size
repeat
especi
fall
near
cutoff
length
repeat
higher
diagnost
predict
hd
penetr
fortun
ldp
current
use
reli
capillari
electrophoresi
accur
determin
repeat
length
attest
excel
perform
cap
profici
survey
busulfan
bifunct
dna
alkyl
agent
typic
given
patient
condit
agent
prior
hematopoiet
cell
transplant
hct
treatment
hematolog
malign
therapeut
drug
monitor
tdm
crucial
safe
efficaci
use
busulfan
due
narrow
therapeut
index
base
area
curv
auc
calcul
low
dose
place
patient
risk
either
graft
failur
earli
relaps
hand
high
dose
increas
risk
neurotox
well
sever
lifethreaten
complic
term
hepat
sinusoid
obstruct
syndrom
so
hepat
so
previous
term
hepat
venoocclus
diseas
vod
refer
occlus
termin
hepat
venul
hepat
sinusoid
sever
case
vod
lead
hepatoren
syndrom
caus
multiorgan
failur
hepat
encephalopathi
death
venoocclus
diseas
typic
occur
context
hct
particularli
administr
condit
regimen
prior
hct
one
fear
complic
hct
account
signific
fraction
hctrelat
mortal
sever
case
account
approxim
so
almost
alway
fatal
despit
clear
need
busulfan
tdm
current
fdaapprov
assay
avail
quantit
busulfan
blood
reason
variou
bioanalyt
method
develop
current
use
multipl
laboratori
data
busulfan
profici
program
organ
univers
washingtonseattl
cancer
care
allianc
show
total
particip
laboratori
present
time
laboratori
use
ga
chromatographi
gc
method
use
hplc
method
use
liquid
chromatographytandem
mass
spectrometri
ms
method
method
nonfdaapprov
test
independ
develop
valid
clinic
use
respect
clinic
laboratori
use
method
also
driven
need
high
precis
accuraci
current
criteria
accept
laboratori
perform
analysi
busulfan
known
concentr
medium
high
concentr
within
known
concentr
low
concentr
due
fact
dose
chang
decis
base
auc
calcul
depend
blood
concentr
busulfan
measur
multipl
time
blood
draw
multipl
small
analyt
error
easili
add
big
differ
calcul
auc
valu
busulfan
test
current
avail
refer
laboratori
howev
mani
busulfan
regimen
call
intraven
infus
everi
hour
day
bone
marrow
transplant
team
need
quicker
turnaround
time
reason
provid
sendout
test
order
abl
make
dose
adjust
within
limit
timespan
guidelin
also
recent
publish
american
societi
blood
marrow
transplant
guidelin
committe
advoc
person
busulfan
dose
use
busulfan
tdm
certain
busulfan
regimen
reason
laboratorydevelop
method
busulfan
continu
play
key
role
manag
hematolog
malign
cancer
center
throughout
world
sensit
measur
serum
androgen
import
adult
pediatr
endocrinolog
oncolog
verylowlevel
testosteron
te
measur
need
adult
women
whose
valu
routin
ngdl
children
men
undergo
antiandrogen
therapi
whose
valu
usual
ngdl
commonli
use
method
steroid
analysi
fdaapprov
immunoassay
rapid
sensit
enough
routin
applic
involv
healthi
adult
male
howev
te
immunoassay
lack
sensit
requir
chemic
castrat
male
women
children
mani
immunoassay
also
lack
specif
accuraci
immunoassay
may
show
crossreact
structur
similar
compound
addit
immunoassay
standard
intern
recogn
standard
reason
number
sensit
specif
assay
use
ms
describ
te
lack
suffici
accuraci
standard
te
assay
major
concern
clinic
public
health
commun
sever
year
ago
endocrin
societi
partnership
cdc
conven
meet
variou
relev
profession
societi
industri
partner
creat
partnership
accur
test
hormon
path
whose
mission
improv
accuraci
standard
varieti
steroid
hormon
test
path
work
cdc
begun
address
concern
host
program
provid
laboratori
specimen
span
analyt
measur
rang
previous
analyz
use
cdc
refer
method
mani
assay
use
ms
approv
cdc
host
program
howev
singl
fdaapprov
immunoassay
met
perform
requir
testosteron
perfect
exampl
ldp
indispens
patient
care
allow
accur
measur
made
children
women
male
patient
cancer
receiv
antiandrogen
medic
ethylen
glycol
colorless
sweettast
liquid
commonli
encount
automobil
antifreez
widespread
avail
also
commonli
encount
toxicolog
agent
accident
selfinflict
poison
exposur
ethylen
glycol
poison
classic
present
metabol
acidosi
caus
product
toxic
metabolit
primarili
glycol
acid
oxal
acid
also
often
accompani
anion
gap
osmol
gap
untreat
ethylen
glycol
poison
also
progress
acut
renal
failur
high
level
oxal
anion
combin
calcium
develop
crystal
kidney
urinari
tract
ethylen
glycol
poison
urgent
toxicolog
emerg
ethylen
glycol
identifi
drug
fomepizol
typic
administ
fomepizol
inhibit
alcohol
dehydrogenas
enzym
metabol
ethylen
glycol
slow
accumul
toxic
metabolit
fomepizol
ethanol
dramat
lengthen
halflif
ethylen
glycol
therefor
hemodialysi
often
requir
clear
poison
diagnosi
treatment
ethylen
glycol
poison
heavili
depend
laboratori
measur
fdaapprov
assay
ethylen
glycol
current
avail
test
perform
laboratorydevelop
procedur
common
method
analysi
ethylen
glycol
gc
flame
ioniz
detector
gc
ms
enzymat
assay
ga
chromatographi
mass
spectrometri
consid
gold
standard
analysi
ethylen
glycol
differenti
interfer
plagu
method
addit
initi
detect
need
diagnosi
ethylen
glycol
blood
concentr
use
determin
hemodialysi
clear
ethylen
glycol
undetect
level
measur
thyroglobulin
tg
serum
proven
use
detect
recurr
treat
differenti
thyroid
carcinoma
dtc
accord
american
cancer
societi
unit
state
new
thyroid
cancer
case
year
death
rate
almost
per
year
differenti
thyroid
cancer
account
case
differenti
thyroid
cancer
produc
tg
make
measur
use
tumor
marker
detect
recurr
nccn
american
thyroid
associ
ata
guidelin
recommend
tg
test
follow
total
thyroidectomi
radioiodin
ablat
treatment
includ
test
baselin
week
treatment
month
month
annual
thereaft
patient
free
diseas
undetect
tg
older
competit
tgria
method
avail
produc
fals
high
tg
result
presenc
tg
autoantibodi
tgab
newer
fdaclear
tg
assay
immunometr
immunoassay
tgia
detect
tg
concentr
approxim
ngml
gener
tg
captur
solidphas
antibodi
quantit
use
detect
antitg
reagent
signal
directli
proport
amount
tg
assay
design
suscept
interfer
endogen
antitgab
intend
use
tgia
tg
measur
tgabneg
tgab
patient
fda
requir
tgab
test
whenev
tg
measur
use
clear
method
depend
method
use
treat
patient
dtc
tgab
posit
tgab
thu
mani
patient
fals
low
even
fals
neg
tg
result
measur
ia
four
tgab
assay
common
use
harmon
detect
tgab
wide
diverg
number
treat
patient
dtc
addit
degre
tg
interfer
predict
magnitud
tgab
result
thu
patient
recurr
miss
tgia
test
circumv
tgab
interfer
hoofnagl
wener
develop
valid
ms
tg
method
tgm
use
tryptic
digest
immunocaptur
tgspecif
peptid
follow
ms
focus
peptid
demonstr
tgm
method
accur
measur
tg
presenc
tgab
tryptic
digest
destroy
tgab
elimin
interfer
assay
four
nation
refer
laboratori
adopt
version
method
harmon
effort
underway
recent
clinic
outcom
studi
compar
tgia
tgria
tgm
tgab
tgab
patient
predict
assay
design
method
equival
tgab
case
tgm
accur
tgab
case
tgia
method
fals
neg
tgria
fals
posit
although
tgm
yet
incorpor
current
guidelin
ata
guidelin
mention
promis
new
techniqu
without
tgm
thyroid
cancer
recurr
tgab
patient
miss
thu
delay
followup
creat
patient
harm
antimicrobi
suscept
test
use
determin
whether
antibiot
treatment
success
essenti
compon
microbiolog
cultur
report
emerg
resist
among
pathogen
bacteria
new
antimicrobi
agent
requir
frequent
updat
test
method
interpret
result
laboratori
use
autom
instrument
perform
minim
inhibitori
concentr
mic
test
determin
whether
patient
isol
bacteria
suscept
suscept
dose
depend
intermedi
resist
panel
antibiot
interpret
base
fda
breakpoint
criteria
publish
time
drug
approv
period
updat
respond
appear
new
resist
mechan
fda
also
clear
autom
instrument
use
determin
mic
valu
via
process
although
mic
test
process
may
chang
new
breakpoint
ad
instrument
softwar
requir
revis
applic
fda
author
requir
manufactur
submit
data
revis
breakpoint
within
specifi
time
frame
manufactur
may
elect
use
outdat
breakpoint
rather
face
expens
resubmiss
recent
exampl
delay
releas
updat
breakpoint
diagnos
carbapenemresist
enterobacteriacea
abil
use
breakpoint
clinic
laboratori
delay
use
calcul
potenti
addit
carrier
multidrugresist
enterobacteriacea
southern
california
healthcar
system
mani
addit
carrier
mdro
enterobacteriacea
estim
occur
orang
counti
california
delay
disastr
spread
mdro
enterobacteriacea
mitig
laboratori
valid
test
method
enabl
use
updat
antimicrobi
breakpoint
interpret
fdaclear
test
avail
specif
modifi
manufactur
instruct
includ
interpret
mic
result
use
revis
breakpoint
list
product
insert
chang
render
procedur
ldp
without
option
use
ldp
one
left
report
outdat
interpret
miss
resist
strain
lead
unaccept
patient
care
illustr
ldp
integr
part
spectrum
test
procedur
perform
clinic
laboratori
fulfil
critic
need
patient
care
particularli
rapidli
evolv
area
test
person
medicin
laboratori
test
consist
nationalintern
consensu
treatment
guidelin
may
requir
develop
procedur
earlier
new
clinic
purpos
fulfil
fdaapprov
kit
case
clinic
test
need
exist
beyond
origin
fda
purpos
laboratori
must
abl
perform
addit
valid
new
sampl
type
develop
addit
assay
includ
new
mutat
analyt
need
illustr
case
exampl
laboratori
profession
organ
often
work
togeth
broadli
compar
optim
assay
perform
creat
consensu
standard
rais
qualiti
test
overal
contrast
current
structur
fda
approv
requir
review
assay
kit
individu
comparison
predic
method
rather
assess
improv
perform
across
spectrum
assay
option
avail
scienc
laboratori
medicin
advanc
dramat
almost
decad
sinc
clia
enact
updat
expans
clia
regul
could
use
addit
resourc
refer
materi
consensu
practic
guidelin
would
extend
qualiti
framework
laboratori
manufactur
util
exampl
consensu
guidelin
includ
detail
target
percent
allel
frequenc
detect
requir
percent
tumor
cell
content
mutat
variant
includ
sampl
type
test
would
use
guid
assay
valid
well
standard
practic
profession
expert
group
alreadi
gener
assay
practic
guidelin
ideal
clinic
laboratori
kit
manufactur
would
util
appropri
refer
materi
help
standard
result
obtain
particular
analyt
regardless
technolog
platform
laboratori
set
address
need
refer
materi
facilit
assay
result
standard
multistakehold
initi
diagnost
qualiti
assur
pilot
launch
design
develop
evalu
traceabl
refer
sampl
materi
refer
refer
materi
better
provid
molecular
patholog
laboratori
mean
demonstr
equival
perform
ldp
companion
diagnost
ivd
target
cancer
therapi
qualiti
pilot
emerg
sustain
predict
oncolog
therapeut
diagnost
work
group
launch
tapestri
network
waltham
massachusett
compos
divers
stakehold
oncologist
pathologist
patient
advoc
third
parti
payer
regul
purpos
design
qualiti
pilot
advanc
goal
http
wwwta
pestrynetworkscominitiativeshealthcareoncologytherapeu
ticsanddiagnosticsdiagnosticqualityassurancepilotcfm
access
april
tapestri
pilot
propos
laboratori
would
allow
util
assay
best
serv
need
patient
base
upon
perform
qualiti
clinic
need
test
menu
volum
particular
laboratori
critic
laboratori
use
ident
assay
test
platform
provid
abl
get
correct
answer
close
overarch
goal
efficaci
safeti
clinic
laboratori
test
procedur
patient
pathologist
laboratori
profession
need
best
uptod
tool
job
optim
patient
care
fda
approv
clear
kit
other
laboratorydevelop
procedur
perform
clia
place
laboratori
long
histori
success
perform
ldp
illustr
case
studi
much
possibl
capabl
need
perform
onsit
insur
result
integr
clinic
laboratori
find
interpret
whole
complet
time
fashion
also
import
handson
train
next
gener
physician
hope
maxim
use
genom
laboratori
inform
way
life
treat
human
diseas
promis
person
medicin
author
declar
potenti
conflict
interest
respect
research
authorship
andor
public
articl
author
receiv
financi
support
research
authorship
andor
public
articl
